Plasma microRNA biomarkers for detection of mild cognitive impairment

Aging

Volumn 4, Issue 9, 2012, Pages 590-605

  Sheinerman, Kira S ^a   Tsivinsky, Vladimir G ^a   Crawford, Fiona ^b   Mullan, Michael J ^b   Abdullah, Laila ^b   Umansky, Samuil R ^a  

^a DiamiR LLC   (United States)

^b ROSKAMP INSTITUTE   (United States)

Author keywords

Aging; Alzheimer's disease; Brain; MicroRNA; Mild Cognitive Impairment (MCI); Neurite; Neurodegeneration; Synapse

Indexed keywords

EID: 84872288330     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100486     Document Type: Article

References (75)

1. Neurodegenerative diseases: From Molecular Concepts to Therapeutic Targets. Editors: R. von Bernhardi, N.C. Inestrosa, Nova Publishers, 2008.
2. 2011 Alzheimer's Disease Facts and Figures. Report of Alzheimer's Association. http://www.alz.org/downloads/Facts_Figures_2011.pdf.
3. DeCarli C. Mild cognitive impairment: prevalence, prognosis, etiology, and treatment. Lancet Neurol. 2003; 2:15-21.
4. Markesbery WR. Neuropathologic Alterations in Mild Cognitive, Impairment: A Review. J. Alzheimers Dis. 2010; 19:221-228.
5. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR Jr, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010; 31:786-799.
6. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58:1985-1992.
7. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002; 59:1594-1599.
8. Brooks LG & Loewenstein DA. Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Therapy. 2010; 2:28-36.
9. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC. (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006; 63:674-681.
10. Khan TK & Alkon DL. Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker. Neurobiol Aging. 2010; 31:889-900.
11. Stephan BCM, Matthews FE, Khaw K-T, Dufouil C & Brayne C. Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Therapy. 2009; 1:4-12.
12. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression to Alzheimer's disease. Alzheimers Res Ther. 2010; 2:2-10.
13. Dlugaj M, Weimar C, Wege N, Verde PE, Gerwig M, Dragano N, Moebus S, Jöckel KH, Erbel R, Siegrist J; Heinz Nixdorf Recall Study Investigative Group. Prevalence of Mild Cognitive Impairment and Its Subtypes in the Heinz Nixdorf Recall Study Cohort. Dement Geriatr Cogn Disord. 2010; 30:362-373.
14. Mariani E, Monastero R & Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis. 2007; 12:23-35.
15. Luck T, Busse A, Hensel A, Angermeyer MC & Riedel-Heller SG. Mild cognitive impairment and development of dementia. Psychiatr Prax. 2008; 35:331-336.
16. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011; 76:1085-1090.
17. Rountree SD, Waring SC, Chan WC, Lupo PJ, Darby EJ, Doody RS Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24:476-482.
18. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of ß- amyloid 1-42, total tau, and P-tau(181) for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011; 68:1137-1144.
19. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010; 67:949-956.
20. Mistur R, Mosconi L, Santi SD, Guzman M, Li Y, Tsui W, de Leon MJ. Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol. 2009; 5:153-166.
21. Miller G. Alzheimer's biomarker initiative hits its stride. Science. 2009; 326:386-389.
22. Schmand B, Eikelenboom P. & van Gool WA. Value of Neurophysiological Tests, Neuroimaging, and Biomarkers for Diagnosing Alzheimer's Disease in Younger and Older Age Cohorts. J Am Geriatr Soc. 2001; 59:1705-1710.
23. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13:1359-1362.
24. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell. 2011; 144:132-142.
25. Nagele E, Han M, Demarshall C, Belinka B, & Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011; 6:e23112.
26. Crews L & Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Human Mol Gen. 2010; 19:R12-R20.
27. Bredesen DE. Neurodegeneration in Alzheimer's disease: caspases and synaptic element independence. Mol Neurodegener. 2009; 4:27-36.
28. Nimmrich V & Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic disfunctions induced byoligomeric beta-amyloid. Rev Neurosci. 2009; 20:1-12.
29. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse Loss and Microglial Activation Precede Tangles in P301S Tauopathy Mouse Model. Neuron. 2007; 53:337-351.
30. Eaton BA & Davis GW. Synapse disassembly. Genes Dev. 2003; 17:2075-2082.
31. Koirala S & Ko C-P. Pruning an Axon Piece by Piece. Neuron. 2004; 44:578-580.
32. Bishop DL, Misgeld T, Walsh MK, Gan W-B & Lichtman JW. Axon branch removal at developing synapses by axosome shedding. Neuron. 2004; 44:651-661.
33. Low LK & Cheng H-J. Axon pruning: an essential step underlying the developmental plasticity of neuronal connections. Phil Trans R Soc B. 2006; 361:1531-1544.
34. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A & Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34, Database issue: D140-D144.
35. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215-233.
36. Brett JO, Renault VM, Rafalski VA, Webb AE, Brunet A. The microRNA cluster miR-106b-25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging (Albany NY). 2011; 3:108-124.
37. McNeill E, Van Vactor D. MicroRNAs Shape the Neuronal Landscape. Neuron. 2012; 75:363-379.
38. Hua Y-J, Tang Z-Y, Tu K, Zhu L, Li Y-X, Xie L, Xiao HS. Identification and target prediction of miRNAs specifically expressed in rat neural tissue. BMC Genomics. 2009; 10:214-225.
39. Liang Y, Ridzon D, Wong L & Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007; 8:166-185.
40. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foà R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129:1401-1414.
41. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA; 2008; 14:35-42.
42. Lugli G, Torvik VI, Larson J & Smalheiser NR. Expression of microRNAs and their precursors in synaptic fractions of adult mouse forebrain. J Neurochem. 2008; 106:650-661.
43. Kye MJ, Liu T, Levy SF, Xu NL, Groves BB, Bonneau R, Lao K, Kosik KS. Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. RNA; 2007; 13:1224-1234.
44. O'Carroll D, Schaefer A. General Principals of miRNA Biogenesis and Regulation in the Brain. Neuropsychopharmacology. 2012 Jun 6. [Epub ahead of print].
45. Schratt G. microRNAs at the synapse. Nat Rev Neurosci. 2009; 10:842-849.
46. Pichardo-Casas I, Goff LA, Swerdel MR, Athie A, Davila J, Ramos-Brossier M, Lapid-Volosin M, Friedman WJ, Hart RP, Vaca L. Expression profiling of synaptic microRNAs from the adult rat brain identifies regional differences and seizure-induced dynamic modulation. Brain Res. 2012; 1436:20-33.
47. Satoh J-i. MicroRNAs and Their Therapeutic Potential for Human Diseases: Aberrant MicroRNA Expression in Alzheimer's Disease Brain. J Pharmacol Sci. 2010; 114:269-275.
48. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008; 14:27-41.
49. Tacutu R, Budovsky A, Yanai H, Fraifeld VE. Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. Aging (Albany NY). 2011; 3:1178-1191.
50. Provost P. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. Aging (Albany NY). 2010; 2:166-169.
51. Yao J, Hennessey T, Flynt A, Lai E, Beal MF, Lin MT. MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One. 2010; 5:e15546.
52. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513-10518.
53. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, Sekiguchi M, Takeda S, Hashido K. Identification of musclespecific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One. 2011; 6:e18388.
54. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2012 Aug 28. [Epub ahead of print].
55. Pichardo-Casas I, Goff LA, Swerdel MR, Athie A, Davila J, Ramos-Brossier M, Lapid-Volosin M, Friedman WJ, Hart RP, Vaca L. Expression profiling of synaptic microRNAs from the adult rat brain identifies regional differences and seizure-induced dynamic modulation. Brain Res. 2012; 1436:20-33.
56. Martinez I, Almstead LL, DiMaio D. MicroRNAs and senescence. Aging (Albany NY). 2011; 3:77-78.
57. Inukai S, de Lencastre A, Turner M, Slack F. Novel MicroRNAs Differentially Expressed during Aging in the Mouse Brain. PLoS One. 2012; 7:e40028.
58. Benhamed M, Herbig U, Ye T, Dejean A, Bischof O. Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells. Nat Cell Biol. 2012; 14:266-275.
59. Smith-Vikos T, Slack FJ. MicroRNAs and their roles in aging. J Cell Sci. 2012; 125(Pt 1):7-17.
60. Li X, Khanna A, Li N, Wang E. Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging. Aging (Albany NY). 2011; 3:985-1002.
61. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:263-269.
62. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:270-279.
63. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:280-292.
64. Abdullah L, Luis C, Paris D, Mouzon B, Ait-Ghezala G, Keegan AP, Wang D, Crawford F, Mullan M. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med. 2009; 15:432-437.
65. Morris J, Heyman A, Mohs R Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989; 39:1159-1165.
66. Wechsler D. (1987) Wechsler Memory Scale - Revised. San Antonio, TX: The Psychological Corporation.
67. Benton A, Sivan A, Hamsher K, Varney N, & Spreen O. (1983) Judgment of Line Orientation. Psychological Assessment Resources, Inc., Lutz, FL.
68. Wechsler D. (1997) Wechsler Adult Intelligence Scale - 3rd Edition. San Antonio, TX: The Psychological Corporation.
69. Luis CA, Abdullah L, Ait-Ghezala G, Mouzon B, Keegan AP, Crawford F, Mullan M. Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum ß-Amyloid. Int. J. Alzheimers Dis. 2011; 2011 Article ID 786264.
70. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-944.
71. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
72. Eng J. Sample Size Estimation: How Many Individuals Should Be Studied? Radiology. 2003; 227:309-313.
73. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008; 14:844-852.
74. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E, Califano JA. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One. 2012; 7:e32307.
75. Matthaei H, Wylie D, Lloyd MB, Dal Molin M, Kemppainen J, Mayo SC, Wolfgang CL, Schulick RD, Langfield L, Andruss BF, Adai AT, Hruban RH, Szafranska-Schwarzbach AE, Maitra A. miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts. Clin Cancer Res. 2012 Aug 21. [Epub ahead of print].